Dermatitis

NEA AWARDS GRANTS FOR ECZEMA RESEARCH TOTALING NEARLY $1 MILLION

Retrieved on: 
Tuesday, December 12, 2023
MSN, Research, Attentional bias, Pediatric Dermatology, Dermatitis, Doctor of Pharmacy, RN, Patient, MSCE, NEA, Science, Pedrá, Harvard College, Atopic dermatitis, Health, National Institutes of Health, NIH, University, MPH, Doctor of Philosophy, Quality of life, Bangladesh Technical Education Board, Inflammation, Pharmaceutical industry, Harbor, Nursing, Management, Boston, MD

NOVATO, Calif., Dec. 12, 2023 /PRNewswire/ -- The National Eczema Association (NEA) today announced the recipients for its 2023 research grants. From both U.S.-based and international applications, the research projects of 18 outstanding investigators were selected, representing grants totaling nearly $1 million. NEA's commitment to innovative eczema research has continued to expand with an increasing number of yearly awardees and an annual investment that has nearly tripled over the past three years.  

Key Points: 
  • From both U.S.-based and international applications, the research projects of 18 outstanding investigators were selected, representing grants totaling nearly $1 million.
  • NEA's commitment to innovative eczema research has continued to expand with an increasing number of yearly awardees and an annual investment that has nearly tripled over the past three years.
  • With 2023 marking the 20th anniversary of its grantmaking, NEA has invested nearly $4 million since its first grant was awarded in 2004.
  • The 2023 research grants were awarded as follows:
    Champion Research Grant– Encourages proven researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema.

A Type of Allergy Medicine Might Help Treat Lung Cancer, Research Suggests

Retrieved on: 
Wednesday, December 6, 2023
DOI, Nature, Marc, Allergy, Cancer research, Patient, Lung cancer, National Institutes of Health, TARGET, Cancer, Doctor of Philosophy, Bangladesh Technical Education Board, Cancer Research Institute, Bristol Myers Squibb, Dermatitis, Immunology, Biomarker, Columbia University, Bone marrow, Immunity, Artificial intelligence, MTR, Austrian Academy of Sciences, CRI, Asthma, AACR, FAAD, Hope, Clinical trial, Mouse, Agency, Immunotherapy, Treatment of lung cancer, Human, SingHealth, Neoplasm, NSCLC, Vaccine, Pharmaceutical industry, Science, Chin, Research, MD

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

Key Points: 
  • Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • "Strikingly, we found that IL-4 blockade enhanced lung cancer response to checkpoint blockade in mice and in six lung cancer patients with treatment-resistant disease.
  • "In our relentless pursuit of progress, the Cancer Research Institute (CRI) proudly supports the visionary team at the Icahn School of Medicine at Mount Sinai.

Frontier Dermatology Expands Community Reach with New Office in Sequim, WA Led by Renowned Dermatologist Dr. Heidi Hermes Shantz

Retrieved on: 
Wednesday, December 6, 2023
Skin cancer, Dermatology, Psoriasis, Dermatitis, Patient, Wart, Pacific Northwest, Acne, Veterinary medicine, Hospital

PORTLAND, Ore. and SEATTLE, Dec. 6, 2023 /PRNewswire/ -- Frontier Dermatology, the leading authority on medical and cosmetic skin care in the Pacific Northwest, is delighted to announce the grand opening of a brand-new, state-of-the-art dermatology clinic in Sequim, Washington on December 7. The new office, located at 565 Eureka Way, will be led by Dr. Heidi Hermes Shantz, an esteemed dermatologist with long-standing ties to the community.

Key Points: 
  • The new office, located at 565 Eureka Way, will be led by Dr. Heidi Hermes Shantz, an esteemed dermatologist with long-standing ties to the community.
  • The Sequim office will provide patients with access to a comprehensive range of dermatological services, including general dermatology for conditions such as acne, eczema, and psoriasis, and select cosmetic dermatology services.
  • New and existing patients may schedule an appointment with Dr. Heidi Hermes Shantz or Haley Gravely by contacting 360-749-8064 (p); 360-994-4975 (f); or by visiting www.FrontierDermatology.com .
  • For more information about Frontier Dermatology and its comprehensive suite of medical and cosmetic skin solutions, please visit www.FrontierDermatology.com .

U.S. Dermatology Partners Relocates Sherman Office to Expanded Facility

Retrieved on: 
Monday, December 4, 2023
Skin cancer, Camping, Tyson Foods, Psoriasis, Dermatitis, Patient, Texas Instruments, Austin College, Diagnosis, Texas Revolution, Dermatology, Grayson College, Acne, Texoma

SHERMAN, Texas, Dec. 4, 2023 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the relocation of its Sherman, Texas, location to a brand new 7,000 sq. ft. office space. The new office is located at 910 E. Pecan Grove Road, in Sherman, Texas, and will open on December 4, 2023. The new office location will improve patients' experience via twelve exam rooms, four Mohs surgical suites, a dedicated phototherapy space, and much more. Patients can expect the same comprehensive care they have become accustomed to from the same great team they already trust. Available services include annual skin examinations, medical dermatology for the treatment of chronic skin conditions, diagnosis and treatment options for skin cancer, and medical-grade skin care products.

Key Points: 
  • SHERMAN, Texas, Dec. 4, 2023 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the relocation of its Sherman , Texas, location to a brand new 7,000 sq.
  • The new office is located at 910 E. Pecan Grove Road, in Sherman, Texas, and will open on December 4, 2023.
  • A staple of the Texoma community, U.S. Dermatology Partners Sherman includes Board-Certified Certified Dermatologists Drs.
  • To schedule an appointment at U.S. Dermatology Partners Sherman , please contact the office at (903) 892-2126 or click here to request an appointment online.

U.S. Dermatology Partners Announces the Opening of Warrensburg, Missouri Office

Retrieved on: 
Monday, November 27, 2023
Johnson County Courthouse, Skin cancer, National academy, Nurse practitioner, Psoriasis, Dermatitis, History, Patient, Partner, University of Central Missouri, Public key certificate, University, Dermatology, Green Elm School, Travel, Acne, Hospital

WARRENSBURG, Mo., Nov. 27, 2023 /PRNewswire-PRWeb/ --  U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Warrensburg, Missouri. This new location is the latest addition to the organization's Outreach Program, which is committed to serving rural and underserved communities. To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states. These new offices, including the Warrensburg location, will provide patients with more convenient access to the care they need and deserve. Beginning November 20th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Johson and Pettis County. Prior to the opening of the U.S. Dermatology Partners office, The nearest dermatology office was located 45 minutes away in Lees Summit, Missouri. The new facility will provide comprehensive care for various dermatologic conditions, including acne, psoriasis, eczema, and skin cancer.

Key Points: 
  • U.S. Dermatology Partners expands access to dermatology care to patients in Johnson and Pettis County by opening the organization's newest office.
  • WARRENSBURG, Mo., Nov. 27, 2023 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Warrensburg, Missouri .
  • Prior to the opening of the U.S. Dermatology Partners office, The nearest dermatology office was located 45 minutes away in Lees Summit, Missouri.
  • Today's announcement builds on U.S. Dermatology Partners' recent openings of offices in St. Joseph, Missouri, Olathe, Kansas, and Canton, Texas.

Diaper (Adult and Baby Diaper) Global Market Insights & Forecast to 2026: Biodegradable Diapers Gain Traction in an Environmentally Conscious World

Retrieved on: 
Thursday, November 23, 2023
Workforce, Irritation, Irritant diaper dermatitis, Woman, Mortality, Skin, Allergy, Groundwater, Infection, Dermatitis

As the number of working women increases, so will the market for baby diapers.

Key Points: 
  • As the number of working women increases, so will the market for baby diapers.
  • Diaper rash is a common form of inflamed skin (dermatitis) that appears as a patchwork of bright red skin on users' bottom.
  • Growing health concern due to the presence of harmful chemicals in the baby diapers is projected to restrict market growth.
  • Sodium polyacrylate is basically used in the baby diapers and this has allergic reactions on the baby skins.

HeiQ unveils HeiQ Skin Care - a probiotics-infused textile technology

Retrieved on: 
Tuesday, November 21, 2023
ISPO, Diet, Acne, Nutritional science, Sleep, Synbiotics, Hormone, Radiation, Gene, Psoriasis, Dermatitis, Irritation, Textile, Leisure, Probiotic, Ageing, HeiQ Materials AG, Rosacea, Red, Skin, Sport, Overalls, Thought, Cosmetics, Smoking, Dietary supplement

HeiQ, a global leader in textile innovation, is proud to announce the launch of HeiQ Skin Care technology for next-to-skin apparel and home textiles.

Key Points: 
  • HeiQ, a global leader in textile innovation, is proud to announce the launch of HeiQ Skin Care technology for next-to-skin apparel and home textiles.
  • HeiQ Skin Care is a synbiotic textile finish aimed at providing a balanced microbiome for glowing skin, even after repeated use and washing of textiles.
  • "HeiQ Skin Care represents a leap forward in textile innovation, combining the power of probiotics and prebiotics to enhance skin microbiome and overall skin appearance.
  • HeiQ Skin Care is suitable for all textile fibers, both natural and synthetic, and can be applied to all textile items that come in direct contact with the skin.

HeiQ unveils HeiQ Skin Care - a probiotics-infused textile technology

Retrieved on: 
Tuesday, November 21, 2023
ISPO, Diet, Acne, Nutritional science, Sleep, Synbiotics, Hormone, Radiation, Gene, Psoriasis, Dermatitis, Irritation, Textile, Leisure, Probiotic, Ageing, HeiQ Materials AG, Rosacea, Red, Skin, Sport, Overalls, Thought, Cosmetics, Smoking, Dietary supplement

HeiQ, a global leader in textile innovation, is proud to announce the launch of HeiQ Skin Care technology for next-to-skin apparel and home textiles.

Key Points: 
  • HeiQ, a global leader in textile innovation, is proud to announce the launch of HeiQ Skin Care technology for next-to-skin apparel and home textiles.
  • HeiQ Skin Care is a synbiotic textile finish aimed at providing a balanced microbiome for glowing skin, even after repeated use and washing of textiles.
  • "HeiQ Skin Care represents a leap forward in textile innovation, combining the power of probiotics and prebiotics to enhance skin microbiome and overall skin appearance.
  • HeiQ Skin Care is suitable for all textile fibers, both natural and synthetic, and can be applied to all textile items that come in direct contact with the skin.

ECZEMAWISE RECOGNIZED WITH TOP PRIZES FROM EHEALTHCARE LEADERSHIP AWARDS FOR SECOND YEAR RUNNING

Retrieved on: 
Monday, November 20, 2023
Sleep, App Store (iOS/iPadOS), Dermatitis, Patient, NEA, Google Play, Caregiver, Mental health, Physician, Quality of life, News, Mobile phone, Nursing

NOVATO, Calif., Nov. 20, 2023 /PRNewswire/ -- The National Eczema Association (NEA) announced that it was presented with multiple top prizes from the eHealthcare Leadership Awards for its app, EczemaWise for the second year in a row. This year, EczemaWise received the Silver prize for Best Mobile App, Best Care/Disease Management and Best Email Content – Email Series. The award recipients in all categories were announced on November 6, 2023. In 2022, EczemaWise was recognized by eHealthcare Leadership Awards with the highest-level Platinum prize in the categories of both Best Care/Disease Management and Best Mobile App.

Key Points: 
  • NOVATO, Calif., Nov. 20, 2023 /PRNewswire/ -- The National Eczema Association (NEA) announced that it was presented with multiple top prizes from the eHealthcare Leadership Awards for its app, EczemaWise for the second year in a row.
  • This year, EczemaWise received the Silver prize for Best Mobile App, Best Care/Disease Management and Best Email Content – Email Series.
  • In 2022, EczemaWise was recognized by eHealthcare Leadership Awards with the highest-level Platinum prize in the categories of both Best Care/Disease Management and Best Mobile App.
  • "We're thrilled to see EczemaWise receive top honors again this year from eHealthcare Leadership Awards, and in multiple categories," said Wendy Smith Begolka, Chief Strategy Officer at NEA.

NEW RESEARCH REVEALS TREATMENT ACCESS BURDENS FOR COMORBIDITIES RELATED TO ECZEMA

Retrieved on: 
Friday, November 17, 2023
Polypharmacy, Research, Asthma, Disease, Dermatitis, Insurance, Patient, NEA, American College, Prescription, Atopic dermatitis, OOP, AAAI, Letter, Face, ACAAI, Pharmaceutical industry, Health insurance

Previous research has revealed that patients with AD often face polypharmacy, high out-of-pocket (OOP) costs, and insurance coverage issues for AD prescriptions.

Key Points: 
  • Previous research has revealed that patients with AD often face polypharmacy, high out-of-pocket (OOP) costs, and insurance coverage issues for AD prescriptions.
  • "We know AD patients can have associated comorbidities that also require prescription treatments, yet we haven't had a holistic view of the access and financial burdens they face."
  • The study also identified opportunities for future research to focus on the impact AD treatments may have on comorbidities.
  • This could lower the need for additional prescription treatments and mitigate the substantial treatment cost and access burdens faced by patients.